In terms of drug type, anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy cause irACEs such as myocarditis; anti-PD-1/PD-L1 treatment causes more related pericardial diseases, and more temporal arteritis is caused by anti-CTLA-4 monotherapy (5). This evidence concerns the gene CTLA4 and myocarditis.